All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub

Brought to you by Scientific Education Support

Scientific Education Support

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My GvHD Hub

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View GvHD content recommended for you

EHA 2019 | What are the current treatment recommendations for acute GvHD and the promotion of the GvL effect?

By Emily Smith,Robert Zeiser

Share:

Featured:

Jun 19, 2019

At the 24th Congress of the European Hematology Association (EHA), Robert Zeiser from the University Medical Center Freiburg, Freiburg, DE, discusses the recommendations for the treatment of acute graft-versus-host disease (GvHD) and the promotion of the graft-versus-leukemia (GvL) effect.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a method used commonly in the treatment of acute myeloid leukemia (AML). Chemotherapy is not curative in these patients, so allo-HSCT can provide an immune effect leading to cure. The side effects of allo-HSCT though include infections and GvHD.

GvHD affects mainly the intestine, liver and skin and whilst there are prophylactic treatments available, it is still a risk, especially since GvHD can become steroid-refractory. Robert Zeiser discusses some of the novel approaches tested for GvHD including JAK inhibitors and immunosuppressive approaches.

The conclusion is that this is an exciting field, with those in the field eagerly awaiting the future developments that are coming.

What are the current treatment recommendations for acute GvHD and the promotion of the GvL effect?

More about...

EHA 2019 Allo-HSCT Acute graft-versus-host disease

Newsletter

Subscribe to get the best content delivered to your inbox